CURRENT OPINION IN ONCOLOGY

Scope & Guideline

Elevating the Discourse in Cancer Research

Introduction

Immerse yourself in the scholarly insights of CURRENT OPINION IN ONCOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1040-8746
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1989 to 2024
AbbreviationCURR OPIN ONCOL / Curr. Opin. Oncol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

CURRENT OPINION IN ONCOLOGY focuses on providing insights and perspectives on the latest advancements and emerging trends in oncology, encompassing a wide range of cancer types and treatment modalities.
  1. Clinical Trials and Safety Reporting:
    The journal emphasizes the importance of meticulous safety reporting in clinical trials, utilizing standardized terminology such as MedDRA to ensure clarity and consistency in safety data presentation.
  2. Sentinel Node Techniques in Oncology:
    A significant focus is placed on sentinel node biopsy techniques across various cancers, particularly gynecologic and breast cancers, highlighting its role in staging, treatment planning, and outcomes.
  3. Innovative Therapeutics:
    The journal explores novel therapeutic approaches, including antibody-drug conjugates and immunotherapies, that are reshaping the landscape of cancer treatment.
  4. Precision Medicine:
    A core area of the journal is the advancement of precision oncology, which tailors treatment strategies based on individual patient profiles, including genetic and molecular characteristics.
  5. Supportive Care and Quality of Life:
    CURRENT OPINION IN ONCOLOGY also addresses the significance of supportive care in enhancing the quality of life for cancer patients, integrating psychosocial aspects into treatment paradigms.
  6. Emerging Technologies:
    The journal highlights the integration of artificial intelligence and machine learning in oncology, examining their potential to improve diagnosis, treatment planning, and patient outcomes.
CURRENT OPINION IN ONCOLOGY is witnessing a dynamic evolution in its thematic focus, reflecting the rapidly changing landscape of cancer research and treatment.
  1. Artificial Intelligence in Oncology:
    There is an increasing trend towards exploring the potential applications of artificial intelligence in cancer therapy, particularly in diagnostics, treatment optimization, and patient management.
  2. Antibody-Drug Conjugates:
    The journal highlights a growing interest in antibody-drug conjugates as a transformative approach in treating various malignancies, showcasing their potential to enhance targeted therapy.
  3. Health Education and Active Prevention:
    Emerging themes include the role of health education in cancer prevention and survivorship, emphasizing the importance of patient engagement and proactive health management.
  4. Integrative and Supportive Oncology:
    There is a rising focus on integrative oncology practices that combine conventional treatments with complementary therapies to improve patient outcomes and quality of life.
  5. Molecular and Genomic Profiling:
    The trend towards precision medicine is underscored by an increasing emphasis on molecular and genomic profiling to guide personalized treatment strategies in oncology.
  6. Survivorship Issues:
    Emerging discussions around survivorship care highlight the need for addressing long-term health outcomes and quality of life for cancer survivors, integrating psychosocial support into treatment models.

Declining or Waning

While the journal covers a broad spectrum of oncology topics, certain themes appear to be diminishing in frequency or prominence in recent publications.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in discussions centered around conventional chemotherapy regimens, as the focus shifts towards novel therapies and combination strategies that offer improved efficacy and reduced toxicity.
  2. General Reviews of Established Treatments:
    The journal seems to be moving away from general reviews of established treatment protocols in favor of more focused studies that explore specific emerging therapies and their mechanisms of action.
  3. Single-Agent Therapies:
    The interest in single-agent therapies appears to be waning, as there is a growing emphasis on combination therapies and multi-modal treatment approaches that enhance effectiveness against complex cancers.

Similar Journals

Tumori Journal

Empowering Oncology Through Innovative Discoveries.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

ANNALS OF ONCOLOGY

Leading the charge in cancer care and clinical practice.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Fostering knowledge and collaboration in oncology.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

ESMO Open

Elevating cancer research with cutting-edge findings.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

Oncology Research and Treatment

Elevating cancer research to new heights.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

ONCOLOGY-NEW YORK

Transforming Cancer Care Through Groundbreaking Research.
Publisher: UBM MEDICAISSN: 0890-9091Frequency: 12 issues/year

ONCOLOGY-NEW YORK is a prominent journal dedicated to the field of oncology, published by UBM MEDICA. Since its inception in 1987, the journal has served as a pivotal platform for disseminating groundbreaking research and advancements in cancer treatment, research, and education. With an ISSN of 0890-9091 and an E-ISSN of 2767-7389, it stands as an accessible resource for professionals, researchers, and students alike. The journal currently holds impressive rankings, categorized within Q3 in Oncology and Q4 in Cancer Research for 2023, reflecting its commitment to high-quality research output and contributions to the field. Despite its challenges in Scopus rankings, positioned at #283/404 in Medicine: Oncology and #188/230 in Biochemistry, Genetics, and Molecular Biology: Cancer Research, ONCOLOGY-NEW YORK continues to primarily focus on innovative cancer therapies and emerging clinical research. The journal's ongoing dedication to enhancing knowledge and understanding in oncology makes it a vital resource for all stakeholders invested in combating cancer.

Journal of Cancer

Bridging knowledge gaps in cancer studies.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

Journal of Adolescent and Young Adult Oncology

Pioneering Research for a Brighter Future in Oncology
Publisher: MARY ANN LIEBERT, INCISSN: 2156-5333Frequency: 6 issues/year

The Journal of Adolescent and Young Adult Oncology, published by MARY ANN LIEBERT, INC, is a premier peer-reviewed journal dedicated to enhancing the understanding and treatment of cancers in adolescents and young adults. With an ISSN of 2156-5333 and an E-ISSN of 2156-535X, this journal specializes in providing vital insights into the unique challenges faced by younger cancer patients, promoting research and clinical best practices in this underrepresented population. The journal features a commendable ranking in the Q2 quartile for Oncology and Q1 quartile for Pediatrics, Perinatology, and Child Health—highlighting its impact and relevance in both fields. Its Scopus rankings also reflect a strong standing; positioned at Rank #107/330 in Pediatrics and Rank #225/404 in Oncology. While the journal operates under a subscription-based model, it aims to disseminate crucial research findings and innovative treatments through its engaging content that serves as an invaluable resource for researchers, clinicians, and students alike. Since its inception in 2014, the journal has been at the forefront of addressing the pressing issues pertinent to young cancer patients, making it a vital outlet for groundbreaking studies and clinical advancements within this critical area of healthcare.

Asia-Pacific Journal of Oncology Nursing

Championing Research that Shapes Oncology Nursing
Publisher: ELSEVIER SCIENCE INCISSN: 2347-5625Frequency: 12 issues/year

Asia-Pacific Journal of Oncology Nursing, published by Elsevier Science Inc, serves as a vital resource for researchers, practitioners, and students involved in the fields of oncology and nursing within the Asia-Pacific region. Since its transition to Open Access in 2014, the journal has aimed to disseminate cutting-edge research and innovative practices that enhance the quality of nursing care in oncology. With its ISSN 2347-5625 and E-ISSN 2349-6673, this journal holds a Q3 rank in both Oncology and Nursing (Oncology Nursing) as of 2023, reflecting its commitment to addressing current challenges and advancements in the discipline. With a Scopus ranking of 252/404 in Medicine (Oncology) and 13/20 in Nursing (Oncology Nursing), it occupies a crucial position in the academic landscape, nurturing knowledge that directly impacts patient care in oncology settings. Located at STE 800, 230 Park Ave, New York, NY 10169, the journal encourages contributions that explore multifaceted aspects of oncology nursing from 2018 to 2024, making it an important platform for emerging voices and established experts alike.

Onkologie

Fostering Knowledge and Innovation in Cancer Treatment.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.